The cytotoxic effect of anticancer drugs has been shown to pases in the execution and not in the trigger phase of drug involve induction of apoptosis. We report here that tumor action. Drug-induced apoptosis was also strongly inhibited cells resistant to CD95 (APO-1/Fas) -mediated apoptosis by antisense approaches targeting caspase-1 and -3, indicatwere cross-resistant to apoptosis-induced by anticancer ing that several members of this protease family were indrugs. Apoptosis induced in tumor cells by cytarabine, doxovolved. CD95-resistant cell lines that failed to activate rubicin, and methotrexate required the activation of ICE/ caspases upon CD95 triggering were cross-resistant to drugCed-3 proteases (caspases), similarly to the CD95 system. mediated apoptosis. Our data strongly support the concept After drug treatment, a strong increase of caspase activity that sensitivity for drug-induced cell death depends on intact was found that preceded cell death. Drug-induced activation apoptosis pathways leading to activation of caspases. The of caspases was also found in ex vivo-derived T-cell leukemia identification of defects in caspase activation may provide cells. Resistance to cell death was conferred by a peptide molecular targets to overcome drug resistance in tumor caspase inhibitor and CrmA, a poxvirus-derived serpin. The cells. peptide inhibitor was effective even if added several hours ᭧ 1997 by The American Society of Hematology. after drug treatment, indicating a direct involvement of cas-
A cytokine. 10, 11 In transfection experiments, caspase-1 can sub-NTICANCER DRUGS have been shown to target diverse cellular functions in mediating cell death in senstitute defective ced-3 in C elegans and is capable of eliciting sitive tumors. Anthracyclines are assumed to induce a genocell death after overexpression in COS or Rat-1 cells. 12 Altoxic effect by damaging DNA, whereas other drugs may though caspase-1 itself can induce apoptosis upon overexinhibit certain metabolic pathways or disrupt the mitotic appression in mammalian cells, mice deficient in caspase-1 paratus. 1 However, the precise molecular requirements that develop normally and, in most cases, cells from these aniare central for drug-mediated cell death are largely unknown. mals are still capable of undergoing apoptosis. 13, 14 Recently, Recently, it has been shown that most antineoplastic drugs a number of other related proteases have been identified used in chemotherapy of leukemias and solid tumors induce that form a multigene family termed caspases. Mammalian apoptosis in drug-sensitive target cells. [2] [3] [4] [5] Apoptosis is a members include caspase-1 (ICE), caspase-2 (Nedd2 and highly conserved physiologic process important in normal Ich-1), caspase-3 (CPP32 and Yama), caspases-4 (TX, Ichdevelopment and tissue homeostasis of multicellular organ-2, and ICE rel II), caspase-5 (ICE rel III and TY), caspaseisms with characteristic morphologic features such as mem-6 (Mch2), caspase-7 (Mch3, ICE-LAP3, and CMH-1), casbrane blebbing and nuclear condensation and fragmentapase-8 (FLICE, MACH, and Mch5), caspase-9 (ICE-LAP6 tion. 6, 7 Physiological apoptosis can be induced by a multitude and Mch6), and caspase-10 (Mch-4) (reviewed in Kumar of stimuli, including withdrawal of growth factors and horand Harvey, 15 Alnemri et al, 16 Martin and Green, 17 Schulzemones, inappropriate expression of oncogenes, and activaOsthoff et al, 18 and Fraser and Evan
19
). Caspases are synthetion of death receptors such as CD95 (APO-1/Fas) and tumor sised as inactive proenzymes that are proteolytically pronecrosis factor-receptor type I (TNF-RI).
cessed to form active heterodimers. 20, 21 Activation may Studies in the nematode Caenorhabditis elegans have proceed through autoproteolysis of the precursor, through been crucial to the identification of critical components of processing by another caspase, or by still undefined prothe cell death machinery. Genetic analyses showed that cesses. A conserved structural motif of most caspases is the apoptosis during development of C elegans embryo is conpentapeptide QACRG surrounding the putative active site trolled by a hierarchical set of genes that include ced-3, cedcysteine residue. 17 As in pro-IL-1b, all caspases require an 4, and ced-9 as key regulators. 6, 8 Ced-3 exhibits significant aspartate residue in P 1 position of the substrate. Poly(ADPhomology with the mammalian protease interleukin-1b (ILribose)polymerase (PARP), an enzyme involved in DNA 1b)-converting enzyme (ICE; caspase-1) 9 that is required repair, is cleaved during apoptosis 22 and has been shown to for proteolytic processing of the IL-1b precursor to the active serve as a substrate for caspase-3. 23 Because single members of the caspase family possess a slightly different substrate specificity and the ability to process each other, one can proaches. 35 Resistance to chemotherapy is a major concern After 10 minutes of further incubation at 37ЊC, the reaction was in cancer treatment. 3 when they showed membrane blebbing and/or a condensed cell nucleus. All experiments were independently evaluated by two scienCells and drug treatment. The human cell lines CEM (acute Ttists in blind samples. At least 180 cells were analyzed for each cell leukemia), SHEP (neuroblastoma), and MG63 (osteosarcoma) condition in three independent experiments. were grown in RPMI-1640 medium supplemented with 10% heatTransfections. Cells were washed in TBS, resuspended at 1 1 inactivated fetal calf serum, 100 U/mL penicillin, 100 mg/mL strepto-10 8 cells/0.4 mL TBS, and transfected with 15 mg of expression mycin, 2 mmol/L L-glutamine (all from GIBCO BRL, Eggenstein, plasmids using a Bio-Rad electroporator (975 mF, 250 V; Bio-Rad, Germany), and 50 mmol/L b-mercaptoethanol (Sigma, Deisenhofen, Richmond, CA). After electroporation, cells were seeded in a 6-well Germany). CD95-resistant cells were generated by continuous culplate at 1 1 10 6 cells/well. Eight hours later, cultures were treated ture in anti-APO-1 (mouse IgG3, 1 mg/mL 40 ) for 3 months. Likewith G418 (1 mg/mL; GIBCO) and incubated for a further 36 hours wise, doxorubicin-resistant cells were isolated after continuous culto select transfected cells. Dead CEM cells were removed by Ficoll ture in increasing concentration (up to 100 ng/mL) of doxorubicin. gradient centrifugation. As determined by cotransfection with the The cytotoxic drugs DX, MT, and CR were purchased from Sigma eukaryotic lacZ expression vector CMV-b-gal (Clontech, Heidelas pure substances. CR and DX were freshly dissolved in sterile berg, Germany) and X-Gal staining, this procedure resulted in the distilled water and MT was dissolved in 0.01 N NaOH before each enrichment of 70% to 90% of transfected SHEP cells and 65% to experiment. The final concentrations of CR, DX, and MT used in 85% of transfected CEM cells. For X-Gal staining, cells were fixed the experiments were 100 mg/mL, 100 ng/mL, and 100 mg/mL, with 1% glutaraldehyde for 5 minutes, washed once with PBS, and respectively.
Measurement of apoptosis. Apoptosis was assessed by the stained for 10 to 12 hours in X-Gal buffer containing 5 mmol/L 6 , 5 mmol/L K 3 Fe(CN) 6 , 2 mmol/L MgCl 2 , and 1 mg/mL
Lysates were separated on a 15% (for caspases and Bcl-2-related proteins) or 8% (for PARP) sodium dodecyl sulfate-polyacrylamide 5-bromo-4-chloro-3-indoxyl-b-galactoside.
Densitometry. Western blot films were photographed using gel electrophoresis under reducing conditions and were transferred onto nitro-cellulose membranes. Proteins were stained with specific HEROLAB (Herolab Molekulare Trenntechnik, Wiesloch, Germany) system and evaluated by the EASY software (provided with antisera against caspase-1, Bcl-2, Bcl-x L (Santa Cruz Biotechnology, Santa Cruz, CA), caspase-2, caspase-3 (Transduction Laboratories, the system). In each case, data from two independent experiments were evaluated. Deviations between experiments were less than 12%.
Lexington, KY), and Bax (Calbiochem, Bad Soden, Germany). An anti-PARP antiserum was kindly provided by Dr J.M. deMurcia Limiting dilution assay. CEM cells were transfected with empty vector, antisense ICE, or CPP32 constructs and selected in G418-(Strasbourg, France). Bound antibodies were detected with a mouse antirabbit/horseradish peroxidase conjugate (Santa Cruz) followed containing medium for 36 hours. Cells were then treated with the indicated cytotoxic drugs. After 30 hours, dead cells were washed by enhanced chemoluminescent (ECL) staining using ECL reagents (Amersham, Braunschweig, Germany). away (Ficoll-Paque) and the remaining ones were adjusted to a concentration of 3 1 cer drugs in leukemia cells. 39 We therefore investigated the bovine serum albumin (GIBCO), the cells were incubated with goat role of caspases in cytotoxic drug-induced apoptosis. Activa- pases that preceded the onset of apoptosis (Fig 1A) . Inmmol/L EDTA, 1 mmol/L phenylmethyl sulfonyl fluoride (PMSF), 1 mg/mL benzamidine, 1 mg/mL aprotinin, and 1 mg/mL leupeptin.
creased cleavage (Ç3-fold) of the substrate was also ob- For personal use only. at EBERHARD KARLS UNIVERSITAET on August 31, 2009. www.bloodjournal.org From served upon treatment with CR, DX, and MT, although both activation of caspases and apoptosis occurred at later time points (Fig 1B through D) . In contrast to anti-APO-1, which caused a sharp peak of activation, drug-induced activation of caspases was maintained at an increased level for 5 to 10 hours. This may suggest that, in contrast to direct death inducers such as CD95, drug-induced apoptosis is less synchronized and may require induction of other signalling molecules or accumulation of cellular changes before activation of caspases. Activation of caspases was confirmed by Western blot analysis detecting proteolytic cleavage of caspases-1, -2, and -3 and PARP upon drug treatment (data not shown). These results suggested that activation of caspases may be crucial for drug-induced apoptosis, similar to the requirement of caspases for an intact CD95 pathway.
Peptide inhibitors of caspases reduce cytotoxic drug-induced apoptosis. To further explore the functional involvement of caspases in drug-induced cell death, we used a tripeptide inhibitor that potently inhibits proteolytic activity of caspases and CD95-mediated apoptosis. zVAD-CH 2 F (zVAD) is an active site inhibitor that mimics the aspartic acid in the P 1 position of known substrates of caspases. Pretreatment of CEM cells with zVAD led to dose-dependent resistance in 60% to 80% of cells towards CR-, DX-, or MT-induced death after 30 hours of drug incubation (Fig  2A) . Similar data were obtained for SHEP neuroblastoma cells (Fig 2B) . A significant percentage (ú50%) of pretreated cells was alive even after prolonged exposure (72 hours). To analyze the level of interference of zVAD with druginduced apoptosis, we either coincubated zVAD together with drugs or delayed addition of zVAD for different periods of time. Protection from drug-induced death could be observed when addition of zVAD was delayed for up to 8 hours after the addition of drugs (Fig 2C) , indicating that inhibition of caspases interfered with a death effector mechanism rather than with a primary target of anticancer drugs. Unrelated protease inhibitors such as leupeptin and PMSF were not able to protect from drug-induced apoptosis (data not shown). The zVAD inhibitor was also effective in MG63 osteosarcoma cells (data not shown), indicating that caspases are involved in drug-induced apoptosis in different chemosensitive tumor cell types.
CrmA, antisense-ICE, and antisense-CPP32 protect cells from drug-induced apoptosis. We next studied whether reduced expression of caspases could inhibit cell death induced by CR, DX, and MT. A number of different caspases have recently been identified in mammalian cells. 15 Although each significantly reduced, although to a lower extent (Fig 3A) . (Fig 3C, a) . Both injected and noninjected cells displayed apoptotic morphology with membrane blebeffects and protection was not significantly enhanced compared with microinjection of the single antisense constructs.
bing, cell shrinkage, and chromatin condensation. In contrast, cells microinjected with CrmA or antisense constructs Similar results were obtained after transfection of the constructs in nonadherent CEM cells by electroporation (Fig  for ICE or CPP32 showed significant resistance against DX (Fig 3C, b through d) . As in CEM or MG63 cells, combined 3B). Subsequently, cells were incubated in G418-containing selection medium resulting in an enrichment of transfected microinjection of antisense-ICE and antisense-CPP32 in SHEP cells was not superior compared with individual concells 65% to 80%. Corresponding to the previous experiment, drug-induced apoptosis in CEM cells was also inhibstructs. This may be due to the fact that both proteases are integral parts of an overlapping pathway or that caspase-3 ited by antisense constructs to a similar extent as CD95- may ultimately become activated through activated caspasesense constructs to downregulate expression of caspases by Western blot. As shown in Fig 4 the pCDNA-3 -a300hICE 2. Antisense-ICE microinjected SHEP cells were able to proliferate (Fig 3C, c) , whereas mitotic divisions were infrewas able to inhibit not only expression of caspase-1 but also significantly reduced expression of caspase-3. On the other quently observed in antisense-CPP32 microinjected cells. Microinjection of MG63 or SHEP cells with empty vector hand, pCDNA-3-a300hCPP32 construct reduced expression of caspase-3 but did not significantly downregulate expresor antisense-ICH-1 did not significantly influenced drug-induced cell death (Fig 3A and C) . To investigate whether sion of caspase-1. Better survival of cells transfected with pCDNA-3-a300hICE could therefore be explained by a inhibition of caspases is also able to provide long-term protection from drug treatment, we further performed limiting broader inhibitory potential. Deficient activation of caspases in doxorubicin-and dilution assays (Fig 3D) . In these experiments, MT, DX, and CR completely killed CEM cells transfected with the paren-CD95-resistant cell lines after anti-APO-1 treatment. Because caspases were shown to be centrally involved in both tal vector even in undiluted cell suspensions. In contrast, samples of cells transfected with antisense-ICE could be drug-and CD95-induced apoptosis, we analyzed caspase activity after incubation with anti-APO-1 in DX-resistant diluted more than 80-fold and still showed living cells 14 days after drug treatment. 36 or imbalance of antiapoptotic and proapoptotic Bcl-2 family members. 38 We therefore investigated whether one of these mechanisms would contribute to the resistance phenotype in our experimental system. Western blot analysis showed no difference in expression levels of Bcl-2, Bcl-x, and Bax proteins in resistant CEM and SHEP cells as compared with the parental cell lines (Fig 6A) . P-gp expression varied among CEM cell lines, with highest expression in sensitive CEM cells, whereas both SHEP and CD95-resistant SHEP cells did not express detectable levels of P-gp (Fig 6B) .
Drug-induced activation of caspases in ex vivo-derived leukemia cells follows the pattern of drug sensitivity. To confirm the data obtained in cell lines, we investigated druginduced activation of caspases in leukemia cells from a patient with T-cell leukemia. Ex vivo-derived leukemia cells were incubated with DX, MT, and CR. After 24 hours, induction of specific apoptosis could be measured with DX (60%) and CR (25%). MT only induced 5% to 10% specific apoptosis. Immunoblot analyses showed that DX and CR treatment indeed yielded the characteristic processed fragments of caspase-1 and PARP (Fig 7) . However, caspase-1 processing and PARP cleavage were only slightly induced after MT treatment. This finding suggests that our basic observations obtained with different cell lines are fundamental to drug sensitivity of primary human cancer cells.
DISCUSSION
Antineoplastic drugs have previously been shown to cause apoptosis similar to known physiologic cell death pathways. 3 We have recently described that DX-induced apoptosis in leukemia cells involves gene expression and induces a cell death mechanism that depends on CD95 ligand-receptor interaction similar to the autocrine suicide in activated T cells. 43 In the present report, we show that chemosensitivity also depends on activation of caspases that are an integral part of the CD95 signalling pathway. Any interference with the activity of these proteases leads to a chemoresistant phenotype. This is supported by different experimental approaches. First, caspase activity is observed in drug-sensitive The physiologic relevance of individual members of the caspase family is presently not well defined. Many cells express more than one of these proteases, but whether all are functionally required for a single apoptotic pathway remains obscure. Current knowledge indicates that single members of the caspase family have distinct substrate specificities, inhibitor profiles, and ability to process each other, 15, 17 suggesting that caspases may form a hierarchical although redundant network that may function as an amplifier for a given apoptotic stimulus. The blocking efficiency of the caspase-3 construct was comparable to a similar antisense construct to caspase-1 in short-term assays, whereas an antisense construct derived from caspase-2 cDNA was considerably of the antisense constructs to known caspases (by BESTFIT; GCG, Madison, WI). Sequence alignment showed the highest overall homology of the anti-ICE construct to known but not drug-resistant derivatives after treatment with drugs.
caspases, which may explain our finding that the anti-ICE Second, interference with caspase activity, either by a pepconstruct also inhibited the expression of other caspases, tide inhibitor or ectopic expression of CrmA, significantly thereby providing the best long-term protective effect in our attenuated drug-induced cytotoxicity. Third, antisense experassays. In contrast, antisense ICH-1, which shows the lowest iments targeting distinct members of caspases lead to a overall homology, may only weakly interfere with synthesis chemoresistant phenotype both in short-term and long-term of other caspases. An important observation is the finding experiments. Lastly, direct activation of certain caspases was that inhibition of caspases not only retarded the apoptotic observed in response to drug treatment by measuring proprocess but also provided protection from drug-induced cessing of relevant caspase precursors and its proteolytic death for up to 2 weeks. Thus, any impairment in the protease activity in all cell lines and patient-derived leukemia cells.
effector phase of apoptosis may lead to chemoresistance Activation of caspases may be the ultimate effector mechaagainst several anticancer drugs. nism in apoptotic pathways induced by different, structurally
The elucidation of cross-resistance between CD95 and unrelated cytotoxic drugs. Malfunction of those death-exeanticancer drugs may have profound implications for the cuting pathways may be clinically reflected as chemoresistreatment of tumors resistant to chemotherapy. Failure to tance. Together with recent reports on activation of caspases activate caspases was not due to other well-characterized on drug treatment [44] [45] [46] and the finding of caspase cleavage resistance mechanisms such as overexpression of antiapoupon drug treatment in primary tumor cells ex vivo, our ptotic Bcl-2-related proteins or increased expression of Pdata indicate that caspases play an important role in drug gp (MDR-1). In addition, consistent with previous reports, 53 sensitivity of tumor cells in vivo.
we found a slight (up to 1.5-fold) increase in intracellular The molecular mechanisms leading to proteolytic activaglutathione levels in resistant cells compared with parental tion of caspases during initiation of apoptosis in general are cell lines (data not shown). Cross-resistance between drugunknown. In the CD95 system, cleavage of caspases may and CD95-mediated apoptosis in some cases may involve be a consequence of the signalling cascade that follows downregulation of CD95 expression 54 (Friesen et al, manumultimerization of the receptor and the assembly of signal script submitted). Our findings indicate that defective downtransduction molecules that become phosphorylated upon stream signalling events such as deficient activation of casbinding to the intracellular death domain of CD95.
47-49 Bepases also contribute to cross-resistance. Defects at the level cause drug-induced activation of caspases requires several of caspase activation may even be more crucial than downhours, additional signalling programs may have to be actiregulation of CD95 for cross-resistance between drug-and vated. Upon drug incubation, CD95 ligand is induced in CD95-mediated apoptosis in view of recently published data leukemia and solid tumor cells and may initiate CD95-medishowing that drug-resistant cell lines that partly reverted ated activation of caspases. 39 However, CD95 ligand is not to sensitivity regained CD95 expression, but still remained induced in MG63 cells after drug treatment (data not shown), resistant to CD95-induced apoptosis. 54 In addition, our findsuggesting that other mechanisms may also lead to activation of caspases in these cells. 
